Asia-Pacific Rx Dermatology Topical Drug Delivery Market – Industry Trends and Forecast to 2026

SUBSCRIBE FOR UPDATED REPORTS

Get great contents delivered straight to your inbox everyday, just a click away, Sign Up Now.
Name
Email
US : +1-888-387-2818
UK : +44 208 089 1725

Asia-Pacific Rx Dermatology Topical Drug Delivery Market – Industry Trends and Forecast to 2026

Asia-Pacific
Publish Reports
  • No of pages :
    350
  • No of Figures:
    19
  • No of Tables:
    92
  • Report Type:
    Publish
  • Category:

Asia-Pacific Rx Dermatology Topical Drug Delivery Market By Product Type (Semi-Solid, Liquid, Solid), Application (Skin Infections, Dermatitis, Antiaging, Acne, Hyperpigmentation, Rosacea, Skin Cancer, Psoriasis, Onychomycosis, Others), Category (Branded, Generic), Countries (Japan, China, India, South Korea, Australia, Thailand, Malaysia, Singapore, Indonesia, Philippines, Rest of Asia-Pacific) – Industry Trends and Forecast to 2026

Topical drugs play an important role in the therapy of dermatologic diseases. Topical dermatology drugs frame a large percentage of products in the drug market. These products are manufactured through specialized manufacturing processes such as precise volume filling, large scale mixing and heating and packaging.

Topical drug administration can be done in the body through ophthalmic, rectal, vaginal and skin as topical routes. In dermatology sector, skin plays a major role for the administration of topical drug for the treatment of skin disease in patients. The topical preparations are applied on the skin for surface, local or systemic effects. The topical formulations include therapeutically active ingredients which help in treating the skin diseases in patients.

Topical drug delivery is one of the most effective ways of drug delivery as it gives optimum therapeutic outcomes. Gradually, the topical drug delivery system has become increasingly important in the pharmaceutical industry. The pharmacological response, both the desired therapeutic effect and the undesired unfavourable effect of a drug is dependent on the concentration of the drug at the place of action, which in turn depends upon the dosage form and the extent of absorption of the drug at the site of action. In dermatology sector, drug molecule applied on the skin which penetrates the skin primarily through the tortuous and continuous intercellular path. These products are available in different forms such as ointments, creams, lotions, gels and others which have the ability to get absorbed in the body and show the positive response in healing wound respectively.

Asia-Pacific Rx dermatology topical drug delivery market is expected to register a healthy CAGR of 5.2% in the forecast period of 2019-2026.

Segmentation: Asia-Pacific Rx Dermatology Topical Drug Delivery Market

The Asia-Pacific Rx dermatology topical drug delivery market is segmented on the basis product type, application and category.

  • On the basis of product type, the market is segmented into solid, liquid and semi-solid. Solid is sub-segmented into powder and others. Liquid is sub-segmented into solution, emulsion, suspension, lotion and others. Semi-solid is sub-segmented into creams, gel, ointments, paste, others.
    • In December 2016, Pfizer Inc. received approval from U.S. Food and Drug Administration (FDA) for the product called EUCRISATM (crisaborole) ointment 2%. It is a novel non-steroidal topical phosphodieterase-4 (PDE-4) inhibitor. It is used for the treatment of mild to moderate atopic dermatitis (AD). With this launch of the product the company has built a heritage in Inflammation and Immunology sector.
  • On the basis of application, the market is segmented into acne, dermatitis, psoriasis, skin infections, antiaging, skin cancer, hyperpigmentation, onychomycosis, rosacea, others.
    • In March 2017, Galderma Laboratories, L.P., makers of Cetaphil brand launched seven new facial skincare products. With this launch of the products Cetaphil portfolio of the company has increased. The company has now broad range of specialized solutions for the patients with skin concerns, including hydration and others.
  • On the basis of category, the market is segmented into generic and branded.
    • In February 2016, Allergan plc received an approval for its product ACZONE (dapsone) Gel, 7.5% from the U.S. Food and Drug Administration (FDA). This product is a new prescription topical treatment which is useful for the treatment of acne in patients 12 years of age and older. The product helped patient in treating acne easily which ultimately helped in increase in revenue.

Competitive Analysis: Asia-Pacific Rx Dermatology Topical Drug Delivery Market

Some of the prominent participants operating in this market are Galderma Laboratories, L.P., Hisamitsu Pharmaceutical Co., Inc., Pfizer Inc., LEO Pharma A/S, GlaxoSmithKline plc., ALLERGAN, Bayer AG, 3M, Bausch Health Companies Inc., The Lubrizol Corporation, Cipla Inc., Kaken Pharmaceutical Co.,Ltd. among others.

Recent Developments:

  • In April 2016, Allergan plc acquired Topokine Therapeutics, Inc. with upfront payment of USD 85.8 million and was eligible to receive contingent development and commercialization milestones of up to USD 260.0 million.
  • In February 2019, Kaken Pharmaceutical Co., Ltd. has concluded an exclusive license and distribution agreement for the topical formulation for Onychomycosis in the People’s Republic of China. According to the agreement Kaken Pharmaceutical Co., Ltd., provided exclusive right for the development and commercialization of the Product in PRC and this has led in high revenue generation.
  • In April 2019, The Lubrizol Corporation launched its newest multifunctional, 2- in-1 rheology modifier, Carbopol Style 2.0 polymer. The product has the benefits for the skin care such as smooth glossy appearance, unique formulation textures and others. With this launch the product portfolio of the company has increased which resulted higher revenue generation.
  • In August 2018, Cipla INC. received final approval for Abbreviated New Drug Application (ANDA) for Diclofenac Sodium Topical Gel, 1% from the U.S. Food and Drug Administration (US FDA). Due to this the company has increased their product portfolio and strong position in market especially in dermatology field.
  • In November 2010, 3M re-launched Cavilon Professional Skin Care line. This product helped in preventing skin damage from moisture, friction and adhesive trauma. The product portfolio of the company has increased in dermatology filed and hence increased healthcare revenue.

Research Methodology: Asia-Pacific Rx Dermatology Topical Drug Delivery Market

Primary Respondents: Key Opinion Leaders (KOL’s): Manufacturer, Healthcare Professionals, Pharmaceutical & Biotechnological Researchers, Doctors & Nurses.

Industry Participants: CEO’s, V.P.’s, Marketing/Product Managers, Market Intelligence Managers and, National Sales Managers.

Choose Licence Type

Enterprise, Single User

TABLE OF CONTENTS ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 RESEARCH METHODOLOGY
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 SECONDARY SOURCES
2.8 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.1.1 INCREASING PREVALENCE OF SKIN DISEASE OR CONDITION
3.1.2 RISING AGING POPULATION
3.1.3 GROWTH IN TOPICAL DRUG DELIVERY
3.1.4 INCREASING RESEARCH AND DEVELOPMENT OF NEW DERMATOLOGICAL DRUGS
3.1.5 NEW PRODUCT LAUNCHES

3.2 RESTRAINTS

3.2.1 WEAK REIMBURSEMENT POLICIES
3.2.2 REGULATORY SCENARIO AND PRICING PRESSURE

3.3 OPPORTUNITIES

3.3.1 LOW BIOLOGIC PENETRATION
3.3.2 INCREASED COMPETITION LEADING TO HIGH INVESTMENTS IN R&D TO INNOVATE NEW PRODUCTS
3.3.3 INCREASING MERGERS AND ACQUISITIONS
3.3.4 EMERGING MARKET

3.4 CHALLENGES

3.4.1 SIDE EFFECTS
3.4.2 PRODUCT RECALL
3.4.3 HIGH COMPETITION
3.4.4 PENETRATION INTO THE SMALLER MARKETS

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE

6.1 OVERVIEW
6.2 SOLID

6.2.1 POWDER
6.2.2 OTHERS

6.3 SEMI-SOLID

6.3.1 CREAMS
6.3.2 GEL
6.3.3 OINTMENTS
6.3.4 PASTE
6.3.5 OTHERS

6.4 LIQUID

6.4.1 SOLUTION
6.4.2 EMULSION
6.4.3 SUSPENSION
6.4.4 LOTION
6.4.5 OTHERS

7 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION

7.1 OVERVIEW
7.2 SKIN INFECTIONS
7.3 DERMATITIS
7.4 ANTIAGING
7.5 ACNE
7.6 HYPERPIGMENTATION
7.7 ROSACEA
7.8 SKIN CANCER
7.9 PSORIASIS
7.10 ONYCHOMYCOSIS
7.11 OTHERS

8 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY

8.1 OVERVIEW
8.2 BRANDED
8.3 GENERIC

9 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY GEOGRAPHY

9.1 ASIA-PACIFIC

9.1.1 JAPAN
9.1.2 CHINA
9.1.3 INDIA
9.1.4 SOUTH KOREA
9.1.5 AUSTRALIA
9.1.6 THAILAND
9.1.7 MALAYSIA
9.1.8 SINGAPORE
9.1.9 INDONESIA
9.1.10 PHILIPPINES
9.1.11 REST OF ASIA-PACIFIC

10 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, COMPANY LANDSCAPE

10.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

11 COMPANY PROFILES

11.1 GLAXOSMITHKLINE

11.1.1 COMPANY OVERVIEW
11.1.2 REVENUE ANALYSIS
11.1.3 COMPANY SHARE ANALYSIS
11.1.4 GEOGRAPHICAL PRESENCE
11.1.5 PRODUCT PORTFOLIO
11.1.6 RECENT DEVELOPMENT

11.2 PFIZER INC.

11.2.1 COMPANY OVERVIEW
11.2.2 REVENUE ANALYSIS
11.2.3 COMPANY SHARE ANALYSIS
11.2.4 GEOGRAPHICAL PRESENCE
11.2.5 PRODUCT PORTFOLIO
11.2.6 RECENT DEVELOPMENTS

11.3 GALDERMA LABORATORIES, L.P.

11.3.1 COMPANY OVERVIEW
11.3.2 COMPANY SHARE ANALYSIS
11.3.3 GEOGRAPHICAL PRESENCE
11.3.4 PRODUCT PORTFOLIO
11.3.5 RECENT DEVELOPMENTS

11.4 LEO PHARMA A/S

11.4.1 COMPANY OVERVIEW
11.4.2 REVENUE ANALYSIS
11.4.3 COMPANY SHARE ANALYSIS
11.4.4 GEOGRAPHICAL PRESENCE
11.4.5 PRODUCT PORTFOLIO
11.4.6 RECENT DEVELOPMENTS

11.5 BAUSCH HEALTH COMPANIES INC.

11.5.1 COMPANY OVERVIEW
11.5.2 REVENUE ANALYSIS
11.5.3 COMPANY SHARE ANALYSIS
11.5.4 GEOGRAPHICAL PRESENCE
11.5.5 PRODUCT PORTFOLIO
11.5.6 RECENT DEVELOPMENT

11.6 ALLERGAN

11.6.1 COMPANY OVERVIEW
11.6.2 REVENUE ANALYSIS
11.6.3 COMPANY SHARE ANALYSIS
11.6.4 GEOGRAPHICAL PRESENCE
11.6.5 PRODUCT PORTFOLIO
11.6.6 RECENT DEVELOPMENTS

11.7 3M

11.7.1 COMPANY OVERVIEW
11.7.2 REVENUE ANALYSIS
11.7.3 GEOGRAPHICAL PRESENCE
11.7.4 PRODUCT PORTFOLIO
11.7.5 RECENT DEVELOPMENT

11.8 BAYER AG

11.8.1 COMPANY OVERVIEW
11.8.2 REVENUE ANALYSIS
11.8.3 GEOGRAPHICAL PRESENCE
11.8.4 PRODUCT PORTFOLIO
11.8.5 RECENT DEVELOPMENTS

11.9 CIPLA INC.

11.9.1 COMPANY OVERVIEW
11.9.2 REVENUE ANALYSIS
11.9.3 GEOGRAPHICAL PRESENCE
11.9.4 PRODUCT PORTFOLIO
11.9.5 RECENT DEVELOPMENT

11.10 HISAMITSU PHARMACEUTICAL CO., INC.

11.10.1 COMPANY OVERVIEW
11.10.2 REVENUE ANALYSIS
11.10.3 GEOGRAPHICAL PRESENCE
11.10.4 PRODUCT PORTFOLIO
11.10.5 RECENT DEVELOPMENT

11.11 KAKEN PHARMACEUTICAL CO.,LTD.

11.11.1 COMPANY OVERVIEW
11.11.2 REVENUE ANALYSIS
11.11.3 GEOGRAPHICAL PRESENCE
11.11.4 PRODUCT PORTFOLIO
11.11.5 RECENT DEVELOPMENTS

11.12 THE LUBRIZOL CORPORATION

11.12.1 COMPANY OVERVIEW
11.12.2 GEOGRAPHICAL PRESENCE
11.12.3 PRODUCT PORTFOLIO
11.12.4 RECENT DEVELOPMENT

12 RELATED REPORTS

LIST OF TABLES ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET

TABLE 1 NUMBER OF FORMULATION COMPONENTS FOR TOPICAL DRUG PRODUCTS MENTIONED BELOW:

TABLE 2 NUMBER AND DISTRIBUTION OF PERSONS AGED 60 YEARS OR OVER BY REGION, IN 2017 AND 2050

TABLE 3 LIST OF APPROVED TOPICAL DRUGS

TABLE 4 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE , 2017-2026 (USD MILLION)

TABLE 5 ASIA-PACIFIC SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 6 ASIA-PACIFIC SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 7 ASIA-PACIFIC SEMI-SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 8 ASIA-PACIFIC SEMI-SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 9 ASIA-PACIFIC LIQUID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 10 ASIA-PACIFIC LIQUID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 11 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION , 2017-2026 (USD MILLION)

TABLE 12 ASIA-PACIFIC SKIN INFECTIONS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 13 ASIA-PACIFIC DERMATITIS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 14 ASIA-PACIFIC ANTIAGING IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 15 ASIA-PACIFIC ACNE IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 16 ASIA-PACIFIC HYPERPIGMENTATION IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 17 ASIA-PACIFIC ROSACEA IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 18 ASIA-PACIFIC SKIN CANCER IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 19 ASIA-PACIFIC PSORIASIS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 20 ASIA-PACIFIC ONYCHOMYCOSIS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 21 ASIA-PACIFIC OTHERS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 22 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY , 2017-2026 (USD MILLION)

TABLE 23 ASIA-PACIFIC BRANDED IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 24 ASIA-PACIFIC GENERIC IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 25 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2026 (USD MILLION)

TABLE 26 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 27 ASIA-PACIFIC SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 28 ASIA-PACIFIC LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 29 ASIA-PACIFIC SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 30 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 31 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION)

TABLE 32 JAPAN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 33 JAPAN SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 34 JAPAN LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 35 JAPAN SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 36 JAPAN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 37 JAPAN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION)

TABLE 38 CHINA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 39 CHINA SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 40 CHINA LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 41 CHINA SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 42 CHINA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 43 CHINA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION)

TABLE 44 INDIA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 45 INDIA SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 46 INDIA LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 47 INDIA SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 48 INDIA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 49 INDIA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION)

TABLE 50 SOUTH KOREA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 51 SOUTH KOREA SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 52 SOUTH KOREA LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 53 SOUTH KOREA SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 54 SOUTH KOREA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 55 SOUTH KOREA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION)

TABLE 56 AUSTRALIA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 57 AUSTRALIA SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 58 AUSTRALIA LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 59 AUSTRALIA SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 60 AUSTRALIA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 61 AUSTRALIA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION)

TABLE 62 THAILAND RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 63 THAILAND SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 64 THAILAND LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 65 THAILAND SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 66 THAILAND RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 67 THAILAND RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION)

TABLE 68 MALAYSIA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 69 MALAYSIA SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 70 MALAYSIA LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 71 MALAYSIA SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 72 MALAYSIA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 73 MALAYSIA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION)

TABLE 74 SINGAPORE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 75 SINGAPORE SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 76 SINGAPORE LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 77 SINGAPORE SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 78 SINGAPORE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 79 SINGAPORE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION)

TABLE 80 INDONESIA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 81 INDONESIA SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 82 INDONESIA LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 83 INDONESIA SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 84 INDONESIA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 85 INDONESIA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION)

TABLE 86 PHILIPPINES RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 87 PHILIPPINES SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 88 PHILIPPINES LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 89 PHILIPPINES SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 90 PHILIPPINES RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 91 PHILIPPINES RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION)

TABLE 92 REST OF ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

LIST OF FIGURES ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET

FIGURE 1 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: GEOGRAPHICAL SCOPE

FIGURE 3 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: DATA TRIANGULATION

FIGURE 4 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: DROC ANALYSIS

FIGURE 5 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 6 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 7 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET

FIGURE 9 TOTAL NUMBER OF COMPANIES WITH ACTIVE PIPELINE (2015 TO 2017)

FIGURE 10 TOTAL NUMBER OF COMPANIES WITH ACTIVE PIPELINE (2012-2017)

FIGURE 11 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: SEGMENTATION

FIGURE 12 INCREASING PREVALENCE OF SKIN DISEASES OR CONDITIONS, RISING AGING POPULATION AND GROWTH IN TOPICAL DRUG DELIVERY ARE EXPECTED TO DRIVE THE ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET IN THE FORECAST PERIOD OF 2019 TO 2026

FIGURE 13 SEMI-SOLID IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC DERMATOLOGY DRUG DELIVERY MARKET IN 2019 & 2026

FIGURE 14 ASIA-PACIFIC IS THE MAXIMUM GROWING AND MOST PROFITABLE REVENUE POCKETS FOR ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET IN THE FORECAST PERIOD OF 2019 TO 2026

FIGURE 15 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: BY PRODUCT TYPE, 2018

FIGURE 16 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: BY APPLICATION, 2018

FIGURE 17 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: BY CATEGORY, 2018

FIGURE 18 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: SNAPSHOT (2018)

FIGURE 19 ASIA-PACIFIC RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE 2018 (%)

Please fill in the below form and our sales representatives will get back to you Shortly

Please fill in the below form and our sales representatives will get back to you Shortly

`